Published in final edited form as:

JAMA Oncol. 2017 March 01; 3(3): 351–357. doi:10.1001/jamaoncol.2016.4188.

Higher serum levels of vitamin D at diagnosis are associated with better survival in a prospective cohort of 1,666 women with breast cancer: A case-cohort analysis in the Pathways Study

Song Yao¹, Marilyn L. Kwan², Isaac J. Ergas², Janise M. Roh², Ting-Yuan David Cheng¹, Chi-Chen Hong¹, Susan E. McCann¹, Li Tang¹, Warren Davis¹, Song Liu³, Charles P. Quesenberry Jr.², Marion M. Lee⁴, Christine B. Ambrosone¹, and Lawrence H. Kushi²

¹Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY

²Division of Research, Kaiser Permanente Northern California, Oakland, CA

³Department of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY

⁴Department of Epidemiology and Biostatistics, University of California, San Francisco, CA

Abstract

Importance—There are long-standing interests in the potential benefits of vitamin D for preventing breast cancer recurrence and mortality; yet data from prospective cohort studies are limited.

Objective—We investigated a serum biomarker of vitamin D status, 25-hydroxyvitamin D (25OHD) measured at the time of breast cancer diagnosis, with prognosis.

Design—The Pathways Study is a prospective cohort study of breast cancer survivors established in 2006. Enrollment was completed in 2013; follow up is ongoing.

Setting—The cohort was established in Kaiser Permanente Northern California (KPNC), a large integrated healthcare delivery system in San Francisco Bay Area and central valley, California.

Participants—Women diagnosed with incident invasive breast cancer were typically consented and enrolled within 2 months of diagnosis. The overall enrollment rate was 46%. Participants are followed for health outcomes and comorbidities at 12, 24, 48, 72 and 96 months after baseline interview. A case-cohort design was used for efficiency assay of 25OHD, selecting 1,666 cohort members with serum samples and ensuring representation in the sub-cohort of races and clinical subtypes.

Main Outcome Measures—Primary outcomes are breast cancer recurrence, second primary cancer (SPC), and death.

Results—Serum 25OHD concentrations were lower in women with advanced stage tumors, and the lowest in premenopausal women with triple-negative cancer. Levels were also inversely associated with hazards of disease progression and death. Compared with the lowest tertile (T1),

Corresponding author: Song Yao, PhD, Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY 14263, Phone: 716-845-4968, song.yao@roswellpark.org.

Conflict of interest: None declared by any coauthors.

women with the highest (T3) 25OHD levels had superior overall survival (OS). This association remained after adjustment for clinical prognostic factors [hazards ratio (HR)=0.72, 95% confidence interval (CI): 0.54, 0.98]. Among premenopausal women, the association with OS was stronger, and there were also associations with breast cancer-specific survival (BCSS) and invasive disease-free survival (IDFS) (OS: HR=0.45, 95% CI, 0.21–0.96; BCSS: HR=0.37, 95% CI, 0.15–0.93; IDFS: HR=0.58, 95% CI, 0.34–1.01; all after full adjustment.)

Conclusions and Relevance—Serum 25OHD levels were independently associated with breast cancer prognostic characteristics and patient prognosis, most prominently among premenopausal women. Our findings from a large, well-characterized prospective cohort provide compelling observational evidence on associations of vitamin D with lower risk of breast cancer morbidity and mortality.

Keywords

Vitamin D; breast cancer; triple-negative subtype; recurrence; mortality; prognosis

Introduction

Vitamin D deficiency has been implicated in a variety of cancers.^{1,2} 25-hydroxyvitamin D (25OHD), the major circulating metabolite, provides a direct assessment of vitamin D status *in vivo*.³ Many epidemiological studies and meta-analyses have investigated the association of blood 25OHD levels with breast cancer risk, reporting mixed results.^{4–9} This could be due, in part, to the etiological heterogeneity of breast cancer. We previously showed that, among premenopausal women, low 25OHD concentrations were associated with advanced tumor stage and triple-negative (TN) subtype.¹⁰

Compared to studies of breast cancer risk, only a few have examined vitamin D with prognosis. Goodwin et al showed higher risk of distant recurrence and death among patients with vitamin D deficiency than those with sufficient levels.¹¹ Although several later studies reported similar findings,^{12–15} two studies reported null associations.^{16,17} It is noted that previous studies invariably examined all-cause mortality, and only one examined breast cancer-specific mortality.¹⁴ Because vitamin D may be related to mortality due to all causes that are not necessarily specific to cancer,^{18–20} it is important to consider breast cancer-specific survival and other outcomes.

In a large prospective cohort of breast cancer survivors, we investigated associations of serum 25OHD with breast cancer prognostic characteristics and outcomes, including recurrence, second primary cancers, and death.

Study Population and Methods

Study population and biospecimen collection

The analyses were conducted within the Pathways Study, a prospective breast cancer cohort of women with breast cancer. Established in January 2006 at Kaiser Permanente Northern California (KPNC), Pathways was designed specifically to examine factors associated with breast cancer recurrence and survival. As previously described,²¹ women diagnosed with

incident invasive breast cancer were identified through rapid case ascertainment, and were typically consented in writing and enrolled within 2 months of diagnosis. The enrollment rate was 46%, and participants were representative of women diagnosed with breast cancer at KPNC during the study period. Baseline interviews were conducted in person and included detailed questionnaires and anthropometric measures; bloods were drawn shortly thereafter. Regular follow-ups are conducted via mailed or phone questionnaires for lifestyle factors at 6, 24, and 72 months, and health outcomes and comorbidities at 12, 24, 48, 72 and 96 months. Blood samples were collected from 90% of the women at a median time of 69 days (range 31–455 days) after diagnosis and shipped to Roswell Park Cancer Institute (RPCI) Data Bank and Biorepository (DBBR) laboratories for processing. The study was approved by the Institutional Review Boards at KPNC and RPCI.

Clinical and outcome data collection

Diagnostic and treatment data were obtained from the KPNC Cancer Registry and other electronic clinical and administrative databases. During follow-up interviews, women reported new breast or other cancers and conditions. On a monthly basis, KPNC electronic medical records were searched for re-initiation of chemotherapy and/or evidence of a potential recurrence using a computerized algorithm of ICD-9/ICD-10 codes, based on research in similar integrated health systems.^{22–25} Potential recurrences identified from both self-report and electronic medical records were confirmed by medical record review. Death information came from several sources, including family members, medical records, and linkage with the KPNC mortality file, which incorporates data from KPNC sources, the State of California, and the Social Security Administration. Underlying cause of death was determined from the death certificate, hospital discharge summary, autopsy or coroner's report, or physician notes.

Breast cancer clinical subtypes were classified using clinical data from KPNC, ascertained using immunohistochemistry (IHC) for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2). For patients with equivocal HER2 status, fluorescence *in situ* hybridization (FISH) is used. Subtypes were defined as: luminal A: ER+ or PR+, and HER2–; luminal B: ER+ or PR+, and HER2+; HER2 enriched: ER–, PR–, and HER2+; and triple-negative: ER–, PR–, and HER2–.²⁶

Case-cohort design and 25OHD measurement

We used a case-cohort design to select a sub-cohort of patients from the total 3,175 participants available at the time. All non-White cases and non-luminal A subtypes were included, along with a random sample of 400 white women with luminal A tumor. We also included women outside the sub-cohort, who had an outcome during this time. In the final subcohort of 1,666 women, serum samples were analyzed for 25OHD concentration by an immunochemiluminometric assay performed at Heartland Assays (Ames, IA). The assay coefficient of variation was 8.8%.

Statistical analysis

Analysis of variance (ANOVA) was used to assess associations of 25OHD concentrations with non-clinical factors that could potentially affect levels, including age at diagnosis,

menopausal status, body mass index (BMI), self-reported race/ethnicity, socioeconomic status (SES), physical activity, smoking, supplementary and dietary vitamin D intake, and season of blood collection. As only weak seasonal variations in 25OHD concentrations were observed in this population (Supplemental Figure s1), we used measured rather than season-adjusted concentrations of vitamin D levels, and accounted for residual confounding by including season in all models. We chose to divide vitamin D levels by tertiles rather than clinical cutpoints (sufficient, insufficient, and deficient), because of controversies over the deficiency definitions and the uncertainty of relevance of such definitions to breast cancer. In additional analyses of vitamin D levels classified by clinical cutpoints (deficient: <20 ng/ml; insufficient: 20–29.9 ng/ml; sufficient: 30 ng/ml),²⁷ the results were similar to those with tertiles.

Serum 25OHD concentrations were compared by known prognostic characteristics at diagnosis, including tumor stage, grade, ER status, and clinical subtype, with adjustment for non-clinical covariates including age at diagnosis, BMI, race/ethnicity, and season of blood collection. Further adjustment for physical activity, smoking, and SES variables in the models did not substantially change the results and were thus omitted. Multinomial logistic regression was used to assess odds ratios (ORs) for 25OHD tertiles with clinical subtypes by IHC, using the most common luminal A subtype as the referent group.

To account for the subcohort sampling scheme, sampling weights were incorporated in ANOVA and multivariable analyses described above, which generated similar estimates.

According to the standardized definitions in the STEEP system,²⁸ survival outcomes assessed included the following: recurrence-free survival (RFS), overall survival (OS), breast cancer-specific survival (BCSS), and invasive disease-free survival (IDFS). IDFS considers recurrence, secondary primary invasive cancers, as well as death due to any causes. We also examined second primary cancers (SPC), including both invasive cancers and ductal carcinoma *in situ* (DCIS). Follow-up began at the time of breast cancer diagnosis until the occurrence of a breast cancer event, and a patient with no event of interest during the follow up was censored at the time of last outcome ascertainment (November 2014). The median follow-up time was 7.0 years (range: 3.7–8.9 years), with 9% loss to active follow up by phone interview (passive follow up by medical records continues).

The associations of serum 25OHD levels with time to each endpoint were examined using multivariable Cox proportional hazards models, modified for the case-cohort design by the method of Langholz and Jiao.²⁹ Minimally-adjusted models included only significant non-clinical covariates (age at diagnosis, BMI, race/ethnicity, and season of blood draw), followed by full adjustment for clinical prognostic factors. Time-covariate interactions were assessed, and no appreciable non-proportionality was found. Interactions were assessed using the Wald test. Non-linearity was tested by including a squared term of ordered vitamin D levels in the models, which was not significant. Only a few covariates were missing with a small proportion and observations with missing data were excluded from the multivariable models by default. All analyses were performed in SAS 9.4 (Cary, NC).

Results

Serum 25OHD concentrations by selected non-clinical factors are summarized in Supplemental Table s1. As expected, concentrations were associated inversely with BMI and positively with physical activity, vitamin D supplement use, and dietary vitamin D intake; African Americans and Hispanics had lower 25OHD concentrations than Whites; and current smokers had lower concentrations than never and former smokers. Older women tended to have higher 25OHD concentrations than younger women. SES variables, including education, household income, and marital status, were also associated. There were statistically significant yet small seasonal variations in 25OHD concentrations. At baseline, almost half (48%) of the patient population were vitamin D deficient, and another 35% insufficient.

As shown in Table 1, there were inverse associations of 25OHD concentrations with tumor stage and tumor grade. The results remained statistically significant for stage after adjustment for covariates, and did not vary by menopausal status (data not shown). No significant differences were found by ER or IHC subtype. Among premenopausal women, however, 25OHD concentrations were the lowest in TN cases (mean: 20.0, 19.8, 19.3, and 18.7 ng/ml for luminal A, luminal B, HER2-enriched and TN, respectively). Using the luminal A subtype as the referent group, premenopausal women with 25OHD levels in the higher two thirds of the distribution had reduced odds of TN subtype than those in the lowest third (T2 vs. T1: adjusted OR=0.45, 95% CI: 0.25, 0.83; T3 vs. T1: OR=0.53, 95% CI: 0.27, 1.04; p for trend=0.03).

Kaplan-Meier survival curves by tertile of serum 25OHD are shown in Figure 1. In multivariable analyses of survival outcomes with adjustment for non-clinical factors, higher 25OHD levels were associated with superior OS (HR=0.54, 95% CI: 0.40, 0.72, p for trend<0.0001), BCSS (HR=0.58, 95% CI: 0.38, 0.90, p for trend=0.01), and IDFS (HR=0.61, 95% CI: 0.44, 0.85, p for trend=0.004), but not with RFS or SPC (model 1 in Table 2). The associations with BCSS and IDFS were attenuated and became non-significant after further adjustment for clinical factors including tumor stage, grade and IHC subtype; while the association with OS remained significant (T3 vs. T1: HR=0.72, 95% CI: 0.54, 0.98, p for trend=0.03; Model 2 in Table 2).

When stratified by menopausal status, higher 25OHD levels were associated with superior RFS, OS, BCSS and IDFS among premenopausal women (survival curves in Supplemental Figure s2; and adjusted HRs in Supplemental Table s2). These associations remained significant after adjustment for non-clinical factors (HR1) and further for clinical factors (HR2). Among postmenopausal women, there were significant associations of 25OHD levels with OS and suggestive associations with IDFS when adjusted for non-clinical factor; both of which, however, became non-significant after further adjustment for clinical factors. Serum 25OHD was not associated with SPC in either pre- or post-menopausal women. Interactions of 25OHD levels with menopausal status on associations with outcomes were non-significant (p for interaction >0.05).

Additional adjustment for treatment regimens (surgery and adjuvant chemotherapy, radiation therapy and hormonal therapy) in the multivariable models already containing clinical prognostic factors did not change the above results.

Discussion

In this case-cohort analysis of serum 25OHD levels with outcomes in a prospective study of women with breast cancer, we found that higher levels of 25OHD were associated with superior prognosis. Women with higher levels of 25OHD had better overall survival, and in premenopausal women, also better breast-cancer-specific survival, recurrence-free survival, and invasive-disease-free survival. No impact of 25OHD levels was observed for risk of second primary cancers.

Several previous studies examined blood 25OHD levels with breast cancer survival outcomes: five reporting superior OS in patients with high 25OHD levels;^{11–15} four remained significant and one became non-significant after adjustment.¹⁴ Our findings are thus consistent with the majority of the literature demonstrating better OS among patients with higher 25OHD levels, following a dose-response pattern. This largely consistent trend was confirmed in two recent meta-analyses.^{4,30} A systematic Cochrane review commissioned by the Institute of Medicine (IOM) also concluded that mortality is probably inversely related to blood 25OHD concentrations among cancer patients.³¹

In addition to OS, recurrence has also been studied with blood 25OHD in the literature, yet the results have been mixed. Three studies reported an inverse association^{11,12,15} and another two^{16,17} reported null associations. In our study, 25OHD levels were not related to RFS in the overall patient population or among postmenopausal women, but an inverse association was found among premenopausal women. Other survival outcomes were only occasionally evaluated in previous studies: BCSS was reported in one study with no association,¹⁴ and SPC was reported in the MA14 trial with no association.¹⁶ While our results of SPC were similar to the MA14 trial, we did observe a significant association of serum 25OHD levels with BCSS in premenopausal women.

The lack of consistency in results of outcomes other than OS may be, in part, due to differences across studies in validity and completeness of data on recurrence, second primary cancers or cause of death. Compared with all-cause mortality, these outcomes might be challenging to track, collect and ascertain, especially when the data are scattered across different providers in the healthcare system. Our study minimizes this limitation by being conducted within a single large integrated healthcare delivery system. There is also a possibility that the consistently observed associations of high blood 25OHD concentrations with lower risk of all-cause mortality reflect more of a general relationship that is not specific to breast cancer patients.^{18–20} We cannot completely refute this possibility, yet the significant associations with RFS and BCSS in our study suggest otherwise.

We advise caution when interpreting our findings of vitamin D with outcomes due to potential residual confounding, given that blood 25OHD concentrations are subject to many environmental and physiological changes. To assess causality and place our findings in the

context of the literature, we adapted the Bradford-Hill criteria as recently discussed by Robsahm et al,^{32,33} regarding the association of vitamin D and cancer. These criteria include temporality, strength, exposure-response, biological plausibility, and consistency. As there is strong biological plausibility of vitamin D's anticancer properties from experimental studies,^{1,2} good consistency across studies of overall survival, and a clear dose-response relationship, we focused our discussion on temporality and confounding effects.

In our study, blood samples were collected typically within 2 months post-diagnosis, a timing likely prior to the development of symptomatic disease progression events. Given that treatment may affect 25OHD levels^{34–37}, we assessed the impact of blood collection time relative to cancer diagnosis and treatment (surgery and initiation of radiation therapy, chemotherapy, or endocrine therapy). Only the time intervals from diagnosis to chemotherapy or endocrine therapy had a moderate influence on measured 25OHD levels. Even so, consideration of timing of blood draw relative to these clinical events did not change associations of 25OHD with outcomes, when the other covariates were already in the models (data not shown). It is also possible that disease severity might adversely impact 25OHD concentrations. Thus, in addition to obesity and other non-clinical factors affecting 25OHD levels, we also adjusted for tumor stage, grade and clinical subtype. Some of the associations were attenuated; yet the associations of 25OHD with OS and among premenopausal women remained. There is also a concern of confounding by the systemic inflammatory response.³⁸ However, the relationship between inflammation and blood 25OHD concentrations is complex and also subject to reverse causation. In fact, vitamin D is known to be anti-inflammatory,^{39,40} and suppression of tumor-caused inflammation may not be confounding, but along the causal pathway of vitamin D's association with breast cancer prognosis.

Based on the above assessment, we tend to agree with the conclusion drawn by Robsahm et al. that the relationship between blood 25OHD and cancer survival may be causal.³³ To definitively prove this, randomized clinical trials (RCTs) of vitamin D supplementation vs. placebo would be necessary. However, in a feasibility study, 84.4% of newly-diagnosed breast cancer patients reported use of vitamin D-containing supplements, and only 12.7% patients met the eligibility criteria,⁴¹ possibly due to increasing public and medical recognition of the issue of vitamin D deficiency. The low levels of deficiency/insufficiency among those cancer patients led the authors to conclude that such an RCT would have limited feasibility. This issue may be further complicated by individuals' changing behaviors of sun exposure and dietary pattern, which may also "contaminate" an RCT schema. Indeed, except for an RCT in UK to test the feasibility of a trial on Vitamin D and Longevity (VIDAL) (<http://vidal.lshtm.ac.uk/>), we are unaware of any other RCTs on vitamin D and cancer survival as the primary endpoint. The ongoing Vitamin D and Omega-3 Trial (VITAL) may eventually provide some data on cancer survival outcomes with continued follow-up;⁴² however, it may take many years to accumulate enough events. In this regard, observational studies like ours from large prospective breast cancer cohorts are valuable to advance our understanding of the relationship between vitamin D and breast cancer survival. In particular, studies of blood levels of vitamin D *per se* – as contrasted with studies of vitamin D supplementation – are not amenable to primary investigation through RCT study designs.

Some limitations of our study should be noted. Although we show stronger associations of 25OHD levels with survival in premenopausal women, interaction testing with menopausal status was not significant. Based on *ad hoc* power calculation, this is likely due to inadequate sample size, especially when the interaction is quantitative, i.e., in the same direction but with different magnitudes of the associations. We did not explicitly control for multiple comparison testing considering the five survival endpoints examined, as our analyses were conducted with *a priori* hypothesis based on the literature and our previous study. Lastly, our classification of IHC subtypes was based on three markers available from the clinical record, ER, PR and HER2. The lack of Ki-67 data may have misclassified some luminal B cases featuring ER/PR-positivity and high Ki-67 as luminal A. However, the proportion of these cases is expected to be small and our main findings are not focused on luminal tumors.

Conclusions

We found that low serum 25OHD levels were associated with poorer survival in this prospective cohort study of women with breast cancer. Furthermore, low serum 25OHD levels were also associated with prognostic characteristics, including TN subtype. The associations with prognostic characteristics and outcomes were independent of each other and were most prominent among premenopausal women. Our findings provide compelling observational evidence for inverse associations between vitamin D levels and risk of breast cancer progression and death.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors thank office and field staff for data collection, processing, and preparation. We thank all Pathways Study participants for their numerous contributions to this study. We also thank Erin K. Weltzien for voluntary assistance in data analysis. Yao S had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. No conflict of interest was declared by any coauthors. The Pathways Study is supported by the National Cancer Institute at the National Institutes of Health (R01 CA105274, PI: Kushi LH; R01 CA166701, PIs: Kwan ML, Yao S; U01 CA195565, PIs: Kushi LH, Ambrosone CB). Vitamin D assays were supported through an American Reinvestment and Recovery Act (ARRA) supplement to the Pathways Study (3R01CA105274-06S1, PI: Kushi LH). Electronic clinical data abstraction and integration was supported in part by the Cancer Research Network (CRN) (U19 CA079689, U24 CA171524, PI: Kushi LH). Blood samples are stored and managed by the Roswell Park Cancer Institute DataBank and BioRepository (DBBR), a Cancer Center Support Grant Shared Resource supported by P30 CA16056 (PI: Johnson CS). Dr. Ambrosone is supported by the Breast Cancer Research Foundation. The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the official views of the funding agencies. The funders played no roles in the design and conduct of the study; in collection, management, analysis, and interpretation of the data; in preparation, review, or approval of the manuscript; or in decision to submit the manuscript for publication.

Funding Support: NIH R01 CA105274; R01CA105274-06S1; R01 CA1667013; U01 CA195565; U19 CA079689; U24 CA171524; P30 CA16056; and Breast Cancer Research Foundation.

References

1. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. *Nat Rev Cancer*. 2007; 7(9):684–700. [PubMed: 17721433]
2. Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. *Nat Rev Cancer*. 2014; 14(5):342–357. [PubMed: 24705652]

3. Bikle DD. Vitamin D metabolism, mechanism of action, and clinical applications. *Chem Biol.* 2014; 21(3):319–329. [PubMed: 24529992]
4. Kim Y, Je Y. Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality: a meta-analysis. *Br J Cancer.* 2014; 110(11):2772–2784. [PubMed: 24714744]
5. Chung M, Lee J, Terasawa T, Lau J, Trikalinos TA. Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. *Ann Intern Med.* 2011; 155(12):827–838. [PubMed: 22184690]
6. Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: serum vitamin D and breast cancer risk. *Eur J Cancer.* 2010; 46(12):2196–2205. [PubMed: 20456946]
7. Chen P, Hu P, Xie D, Qin Y, Wang F, Wang H. Meta-analysis of vitamin D, calcium and the prevention of breast cancer. *Breast Cancer Res Treatment.* 2010; 121(2):469–477.
8. Cui Y, Rohan TE. Vitamin D, calcium, and breast cancer risk: a review. *Cancer Epidemiol Biomarkers Prev.* 2006; 15(8):1427–1437. [PubMed: 16896028]
9. Chlebowski RT. Vitamin D and breast cancer: interpreting current evidence. *Breast Cancer Res.* 2011; 13(4):217. [PubMed: 21884640]
10. Yao S, Sucheston LE, Millen AE, et al. Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prognostic characteristics: a case-control and a case-series study. *PLoS one.* 2011; 6(2):e17251. [PubMed: 21386992]
11. Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. *J Clin Oncol.* 2009; 27(23):3757–3763. [PubMed: 19451439]
12. Hatse S, Lambrechts D, Verstuyf A, et al. Vitamin D status at breast cancer diagnosis: correlation with tumor characteristics, disease outcome, and genetic determinants of vitamin D insufficiency. *Carcinogenesis.* 2012; 33(7):1319–1326. [PubMed: 22623648]
13. Tretli S, Schwartz GG, Torjesen PA, Røksahm TE. Serum levels of 25-hydroxyvitamin D and survival in Norwegian patients with cancer of breast, colon, lung, and lymphoma: a population-based study. *Cancer Causes Control.* 2012; 23(2):363–370. [PubMed: 22193397]
14. Villaseñor A, Ballard-Barbash R, Ambis A, et al. Associations of serum 25-hydroxyvitamin D with overall and breast cancer-specific mortality in a multiethnic cohort of breast cancer survivors. *Cancer Causes Control.* 2013; 24(4):759–767. [PubMed: 23361338]
15. Vrieling A, Hein R, Abbas S, Schneeweiss A, Flesch-Janys D, Chang-Claude J. Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study. *Breast Cancer Res.* 2011; 13(4):R74. [PubMed: 21791049]
16. Piura E, Chapman JW, Lipton A, et al. Serum 1-OH vitamin D (D) and prognosis of postmenopausal breast cancer (BC) patients: NCIC-CTG MA14 trial. *J Clin Oncol.* 2009; 27(15s):534.
17. Jacobs ET, Thomson CA, Flatt SW, et al. Vitamin D and breast cancer recurrence in the Women's Healthy Eating and Living (WHEL) Study. *Am J Clin Nutr.* 2011; 93(1):108–117. [PubMed: 20980485]
18. Sempos CT, Durazo-Arvizu RA, Dawson-Hughes B, et al. Is there a reverse J-shaped association between 25-hydroxyvitamin D and all-cause mortality? Results from the U.S. nationally representative NHANES. *J Clin Endocrinol Metab.* 2013; 98(7):3001–3009. [PubMed: 23666975]
19. Durup D, Jorgensen HL, Christensen J, Schwarz P, Heegaard AM, Lind B. A reverse J-shaped association of all-cause mortality with serum 25-hydroxyvitamin D in general practice: the CopD study. *J Clin Endocrinol Metab.* 2012; 97(8):2644–2652. [PubMed: 22573406]
20. Schottker B, Jorde R, Peasey A, et al. Vitamin D and mortality: meta-analysis of individual participant data from a large consortium of cohort studies from Europe and the United States. *BMJ.* 2014; 348:g3656. [PubMed: 24938302]
21. Kwan ML, Ambrosone CB, Lee MM, et al. The Pathways Study: a prospective study of breast cancer survivorship within Kaiser Permanente Northern California. *Cancer Causes Control.* 2008; 19(10):1065–1076. [PubMed: 18478338]
22. Kroenke CH, Chubak J, Johnson L, Castillo A, Weltzien E, Caan BJ. Enhancing Breast Cancer Recurrence Algorithms Through Selective Use of Medical Record Data. *J Natl Cancer Inst.* 2016; 108(3)

23. Haque R, Shi J, Schottinger JE, et al. A hybrid approach to identify subsequent breast cancer using pathology and automated health information data. *Med Care*. 2015; 53(4):380–385. [PubMed: 25769058]
24. Hassett MJ, Ritzwoller DP, Taback N, et al. Validating billing/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using 2 large contemporary cohorts. *Med Care*. 2014; 52(10):e65–73. [PubMed: 23222531]
25. Chubak J, Yu O, Pocobelli G, et al. Administrative data algorithms to identify second breast cancer events following early-stage invasive breast cancer. *J Natl Cancer Inst*. 2012; 104(12):931–940. [PubMed: 22547340]
26. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. *JAMA*. 2006; 295(21):2492–2502. [PubMed: 16757721]
27. Holick MF. Vitamin D deficiency. *New Engl J Med*. 2007; 357(3):266–281. [PubMed: 17634462]
28. Hudis CA, Barlow WE, Costantino JP, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. *J Clin Oncol*. 2007; 25(15):2127–2132. [PubMed: 17513820]
29. Langholz B, Jiao J. Computational methods for case-cohort studies. *Comp Statist Data Anal*. 2007; 51(8):3737–3748.
30. Mohr SB, Gorham ED, Kim J, Hofflich H, Garland CF. Meta-analysis of vitamin D sufficiency for improving survival of patients with breast cancer. *Anticancer Res*. 2014; 34(3):1163–1166. [PubMed: 24596354]
31. Bjelakovic G, Gluud LL, Nikolova D, et al. Vitamin D supplementation for prevention of mortality in adults. *Cochrane Database Syst Rev*. 2011; (7):CD007470. [PubMed: 21735411]
32. Hill AB. The Environment and Disease: Association or Causation? *Proc R Soc Med*. 1965; 58:295–300. [PubMed: 14283879]
33. Robsahm TE, Schwartz GG, Tretli S. The Inverse Relationship between 25-Hydroxyvitamin D and Cancer Survival: Discussion of Causation. *Cancers*. 2013; 5(4):1439–1455. [PubMed: 24202453]
34. Reid D, Toole BJ, Knox S, et al. The relation between acute changes in the systemic inflammatory response and plasma 25-hydroxyvitamin D concentrations after elective knee arthroplasty. *Am J Clin Nutr*. 2011; 93(5):1006–1011. [PubMed: 21411617]
35. Heaney RP. Serum 25-hydroxyvitamin D is a reliable indicator of vitamin D status. *Am J Clin Nutr*. 2011; 94(2):619–620. author reply 620. [PubMed: 21775574]
36. Kim HJ, Koh BS, Yu JH, et al. Changes in serum hydroxyvitamin D levels of breast cancer patients during tamoxifen treatment or chemotherapy in premenopausal breast cancer patients. *Eur J Cancer*. 2014; 50(8):1403–1411. [PubMed: 24703104]
37. Crew KD, Shane E, Cremers S, McMahon DJ, Irani D, Hershman DL. High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. *J Clin Oncol*. 2009; 27(13):2151–2156. [PubMed: 19349547]
38. Conway FJ, McMillan DC. Plasma vitamin D concentration and survival in colorectal cancer: potential confounding by the systemic inflammatory response. *J Clin Oncol*. 2015; 33(2):224.
39. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. *Am J Clin Nutr*. 2006; 83(4):754–759. [PubMed: 16600924]
40. Mangin M, Sinha R, Fincher K. Inflammation and vitamin D: the infection connection. *Inflamm Res*. 2014; 63(10):803–819. [PubMed: 25048990]
41. Cescon DW, Ganz PA, Beddows S, Ennis M, Mills BK, Goodwin PJ. Feasibility of a randomized controlled trial of vitamin D vs. placebo in women with recently diagnosed breast cancer. *Breast Cancer Res Treatment*. 2012; 134(2):759–767.
42. Pradhan AD, Manson JE. Update on the Vitamin D and Omega-3 trial (VITAL). *J Steroid Biochem Mol Biol*. 2016; 155(Pt B):252–256. [PubMed: 25864623]

Figure 1.

Kaplan-Meier survival curves by tertiles of serum 25-hydroxyvitamin D levels. Numbers of patients at risk are provided at the bottom part of the plots. **A).** Recurrence-free survival; **B).** Overall survival; **C).** Breast cancer-specific survival; **D).** Invasive disease-free survival.

Table 1

Multivariable-adjusted serum 25-hydroxyvitamin D levels by breast cancer prognostic characteristics in the Pathways Study cohort

	N (%)	LS Mean (95% CI), ng/ml	P-value
AJCC stage			<0.0001
I	824	21.5 (20.9–22.1)	
II	606	19.3 (18.6–20.0)	
III	202	19.0 (17.8–20.2)	
IV	34	18.4 (15.7–21.2)	
Tumor grade			0.15
Well differentiated	329	20.8 (19.9–21.8)	
Moderately differentiated	675	20.5 (19.9–21.2)	
Poorly differentiated	559	19.8 (19.0–20.6)	
Estrogen receptor status			0.95
Positive	1,226	20.4 (19.8–20.9)	
Negative	440	20.3 (19.5–21.2)	
Clinical subtype by IHC			0.56
Luminal A	1,000	20.4 (19.9–21.0)	
Luminal B	213	19.8 (18.7–21.0)	
HER2-enriched	113	21.0 (19.4–22.6)	
Triple-negative	323	20.0 (19.1–21.0)	

Least square means (LS Mean) and 95% confidence interval (CI) after adjustment for age at diagnosis, body mass index at baseline, race/ethnicity, and season of blood collection. Definition of clinical subtype by IHC: luminal A: ER+ and/or PR+, and HER2–; luminal B: ER+ and/or PR+, and HER2+; HER2 enriched: ER–, PR–, HER2+; triple-negative, ER–, PR–, HER2–

Table 2

Multivariable-adjusted associations of tertiles of serum 25-hydroxyvitamin D levels with survival outcomes in the Pathways Study cohort

25OHD level	#event/total	HR1 (95% CI)	HR2 (95% CI)
Recurrence-free survival (RFS)			
T1	71/520	1.00	1.00
T2	59/521	0.76 (0.55–1.06)	0.87 (0.62–1.21)
T3	70/525	0.98 (0.71–1.36)	1.13 (0.82–1.58)
P for trend		0.88	0.47
Overall survival (OS)			
T1	100/520	1.00	1.00
T2	74/521	0.61 (0.46–0.80)	0.78 (0.59–1.04)
T3	76/525	0.54 (0.40–0.72)	0.72 (0.54–0.98)
P for trend		<0.0001	0.03
Breast cancer-specific survival (BCSS)			
T1	51/520	1.00	1.00
T2	45/521	0.81 (0.55–1.19)	1.12 (0.76–1.67)
T3	37/525	0.58 (0.38–0.90)	0.85 (0.55–1.33)
P for trend		0.01	0.53
Invasive disease-free survival (IDFS)			
T1	137/520	1.00	1.00
T2	116/521	0.63 (0.45–0.88)	0.81 (0.57–1.14)
T3	119/525	0.61 (0.44–0.85)	0.85 (0.60–1.20)
P for trend		0.004	0.36
Second primary cancer-free survival (SPCFS)			
T1	30/520	1.00	1.00
T2	34/521	0.98 (0.61–1.59)	0.98 (0.61–1.60)
T3	32/525	0.89 (0.54–1.46)	0.84 (0.51–1.39)
P for trend		0.64	0.49

HR1: adjusted for age at diagnosis, race/ethnicity, body mass index, and season of blood collection. HR2: adjusted additionally for tumor stage, grade and IHC subtype. Cutoff points for serum 25OHD levels: T1: <16.75 ng/ml; T2: 16.75–25.09 ng/ml; T3: ≥25.10 ng/ml. Further adjustment for cancer treatment (surgery, radiation therapy, chemotherapy and endocrine therapy) on the basis of HR2 models did not substantially changed the results. The P for trend test was done by treating the tertiles as an ordered value in the models.